Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Nazartinib |
| Synonyms | |
| Therapy Description |
Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Nazartinib | EGF816 | EGFR Inhibitor 3rd gen 19 | Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB2 L869R | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L869R in culture (PMID: 31588020). | 31588020 |
| ERBB2 D769Y | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
| ERBB2 V842I | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V842I were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 D769N | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769N in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 G778_P780dup | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 L755P | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L755P were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 G776delinsVC | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 G776delinsLC | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsLC were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 L786V | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 |
| ERBB2 G778_S779insLPS | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 V773M | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 G776delinsVV | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVV were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
| ERBB2 L755S | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020). | 31588020 |
| ERBB2 V777L | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020). | 31588020 |
| ERBB2 D769H | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769H in culture (PMID: 31588020). | 31588020 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT02108964 | Phase Ib/II | Nazartinib | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | Active, not recruiting |
CKB BOOST